<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The association between CMV reactivation and relapse was evaluated in a large cohort of patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) (n=761), <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) (n=322), <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) (n=646), <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n=254), and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) (n=371) who underwent allogeneic hematopoietic cell transplantation (HCT) between 1995 and 2005 </plain></SENT>
<SENT sid="1" pm="."><plain>In multivariable models, CMV pp65 antigenemia was associated with a decreased risk of relapse by day 100 among patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (HR 0.56, 95%CI 0.3-0.9), but not in patients with ALL, <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, <z:mp ids='MP_0005481'>CML</z:mp> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The effect appeared to be independent of CMV <z:mp ids='MP_0001799'>viral</z:mp> load, <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft versus host disease</z:e> or <z:chebi fb="0" ids="465284">ganciclovir</z:chebi>-associated <z:hpo ids='HP_0001875'>neutropenia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>At 1 year after HCT, early CMV reactivation was associated with reduced risk of relapse in <z:hpo ids='HP_0000001'>all</z:hpo> patients but this did not reach significance for any disease subgroup </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, CMV reactivation was associated with increased non-relapse mortality (HR 1.31, 95% CI 1.1-1.6) and no difference in overall mortality (HR 1.05, 95% CI 0.9-1.3) </plain></SENT>
<SENT sid="5" pm="."><plain>This report demonstrates a modest reduction in early relapse risk after HCT associated with CMV reactivation in a large cohort of patients, without a benefit in overall survival </plain></SENT>
</text></document>